Cure8 research brief
The review connects microbiome-targeted therapies (diet, probiotics, FMT, antibiotics, and newer approaches) to mechanisms relevant to IBD and systemic health, highlighting why these strategies are of interest to patients and clinicians.
Clinicians; researchers; adult patients with IBD or IBS interested in microbiome-based therapies; those following microbiome research and therapeutic development.
The paper identifies five core molecular pathways through which microbiome-targeted therapies may work: competitive pathogen exclusion, epithelial barrier reinforcement, immune modulation, short-chain fatty acid production, and neurotransmitter signaling.
Clinical interventions discussed include dietary approaches, probiotics/prebiotics/synbiotics/postbiotics, fecal microbiota transplantation (FMT), antibiotics like rifaximin, psychobiotics, bacteriophage therapy, and lifestyle changes.
The authors propose a three-tier translational framework linking molecular mechanisms to GI outcomes and potential systemic benefits, and they emphasize the need for standardized trial designs and precision approaches before broad clinical translation.
This is a narrative review (2012–2024 sources) summarizing mechanisms and clinical evidence; it does not present new trial data. The authors call for standardized trials and precision approaches to translate findings into practice.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
IBD and other lower-GI disorders may benefit from oral hydrogel platforms that improve local drug delivery while deliberately engaging the gut microbiota. Understanding this research direction helps patients and...
This study offers a noninflammatory explanation for why many people with Crohn’s continue to have symptoms despite controlled inflammation: sulfur-producing gut microbes and their hydrogen sulfide byproduct. That could...
This study suggests machine learning of stool microbiome data could eventually help distinguish IBD (especially Crohn’s) from healthy people and some other bowel or systemic conditions.
